33rd week of 2013 patent applcation highlights part 40 |
Patent application number | Title | Published |
20130209365 | Anti-C-Met Antibody and Methods of Use Thereof - Antibodies that bind to c-Met are provided herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies and diagnostics. In certain embodiments, antibodies bind mammalian cell surface antigen (e.g., cancer cell surface antigen). The antibodies can also be endocytosed upon binding to cells. Cells that can be targeted by the antibodies include carcinomas, such as those in lung, kidney, liver, stomach, breast, and brain, etc. | 2013-08-15 |
20130209366 | Glutathione-Lanthionine Compounds and Methods Related Thereto - The present invention concerns glutathione-lanthionine compounds, the process of preparing such compounds, and their use. The invention also concerns methods of using the compounds and derivatives and combinations of these compounds in the treatment and/or prevention diseases, including diseases affecting the central nervous system. | 2013-08-15 |
20130209367 | PARTICLE AND CONTRAST AGENT HAVING THE PARTICLE - There is provided an ICG-loaded polymer nanoparticle that is dynamically stable, prevents the leakage of contained ICG and the resulting discoloration, and has a high molar absorbance coefficient. The particle contains a hydrophilic dye having a sulfonate group and a hydrophobic polymer, and the particle further contains at least one of a lipid having a positively charged region, a nicotinic acid derivative and a thiamine derivative. | 2013-08-15 |
20130209368 | NEAR INFRARED FLUORESCENT PARTICLES AND USES THEREOF - The present invention provides particles comprising either a water-soluble polymer or a phospholipid, wherein at least one near infrared (NIR) fluorescent probe and optionally at least one active agent such as a targeting moiety, capable of selectively recognizing a particular cellular marker, are non-covalently bound to the outer surface of the particles. Pharmaceutical compositions comprising these particles may be used, inter alia, for detection and treatment of tumors in the gastrointestinal tract | 2013-08-15 |
20130209369 | NANOPARTICLES BASED ON GADOLIIUM COORDINATION POLYMERS AS HIGHLY SENSITIVE T1 MRI CONTRAST AGENTS - An agent for imaging of a biological system or delivering drugs to a biological system including one or more nanoparticles formed of at least one gadolinium coordination polymer. | 2013-08-15 |
20130209370 | INJECTABLE VOID FILLER FOR SOFT TISSUE AUGMENTATION - The present invention teaches a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler. The composition of the present application exhibits physical characteristics, such as mechanical properties, typically seen in elastomers and mechanical stability, which is superior to fibrin alone. A variety of properties of the composition of the present invention can be effectively fine-tuned and altered by adjusting type and content of the particles as well as of the plasticizer contained in the void filler composition. | 2013-08-15 |
20130209371 | Germ Solve Candle - A candle is provided which includes a unique blend of ingredients that been formulated to reduce a broad spectrum of germs in the area of the candle of the present invention, as well as weakening the spread of infectious contaminates imposed by coughing and sneezing, in the area surrounding the candle of the present invention. | 2013-08-15 |
20130209372 | LYOPHILIZED BIOPESTICIDE EFFERVESCENT GRANULE AND PRODUCTION METHOD THEREOF - The present invention relates to a granulated lyophilized effervescent biopesticide granule and production method ( | 2013-08-15 |
20130209373 | TUBE FEED PACKAGES AND METHODS FOR USING SAME - Nutritional compositions that mimic whole foods and methods of using the nutritional compositions are provided. The nutritional compositions may include an increased number and variety of fruits and vegetables, an increased variety of macronutrient sources and an increased amount of other components that are found in whole foods. The nutritional compositions may also include ethnicity-specific meals and organic ingredients and provide emotional appeal to the patient and/or the patient's caregiver. Methods of administering such nutritional compositions to patients in need of same are also provided | 2013-08-15 |
20130209374 | PROBIOTIC COMPOSITION FOR ORAL HEALTH - The present invention provides a composition comprising an effective amount of | 2013-08-15 |
20130209375 | ORAL CARE COMPOSITION COMPRISING DISSOLVED TIN AND FLUORIDE - An oral care composition comprising a liquid phase containing 30% to 90%, preferably 30% to 80% by weight, based on the liquid phase, of water; dissolved tin; 200 to 2000 ppm fluoride ions, based on the oral composition; and 5 to 60% by weight, based on the oral care composition, of a C | 2013-08-15 |
20130209376 | ORAL CARE COMPOSITIONS - Oral care compositions containing an oral care ingredient and a thickening agent, wherein the thickening agent comprises a strongly swellable, lightly to moderately crosslinked polyvinyl pyrrolidone. The polyvinyl pyrrolidone thickening agent is characterized by an aqueous gel volume of about 15 to 150 ml/g and a Brookfield viscosity of at least 10,000 cps for a 5% aqueous solution at 25° C. | 2013-08-15 |
20130209377 | Synthesis of Amorphous Calcium Phosphate or Poorly Crystalline Calcium Phosphate Powders by Using Ca Metal - The present invention relates to the synthesis of bioceramics, in particular, of amorphous or cryptocrystalline calcium phosphates. | 2013-08-15 |
20130209378 | SKIN CONDITIONING AND LUBRICATING CREME, AND METHOD OF MAKING AND USING SAME - A cosmetic agent that takes the place of powdered talc is described herein. The present cosmetic agent is a skin conditioning and lubricating crème comprising talc; at least one volatile silicone fluid; at least one structuring component; and at least one emollient. The inventive composition provides skin conditioning and lubrication without the inconveniences inherent in using powdered products such as talcum powder. | 2013-08-15 |
20130209379 | LIP COSMETIC FORMULATIONS - Cosmetic formulations suitable for application to the lips are described herein. The lip cosmetic formulations can contain at least caffeine, extract of | 2013-08-15 |
20130209380 | MOISTURIZING COMPOSITION WITH SPF 30 - Described is a composition for topical application in the form of a moisturizing composition including zinc gluconate and at least one UVA/UVB sunscreen as a moisturizering ingredient, and the use thereof as a cosmetic or a pharmaceutical product. The composition is intended for use in the treatment of acne. | 2013-08-15 |
20130209381 | TOPICAL APPLICATION OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS/AFFLICTIONS - Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin. | 2013-08-15 |
20130209382 | SKIN CARE COMPOSITIONS - Described are skin care compositions comprising an aqueous dispersion comprising a metallocene catalyzed polyolefin, an ethylene acrylic acid copolymer, or a combination thereof. | 2013-08-15 |
20130209383 | SERIES OF SKIN WHITENING (LIGHTENING) COMPOUNDS - The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin. | 2013-08-15 |
20130209384 | TREATMENT AND COMPOSITION FOR ACHIEVING SKIN ANTI-AGING BENEFITS BY CORNEUM PROTEASE ACTIVATION - Disclosed is a method of brightening skin or evening out the tone of skin comprising topically applying to skin in need thereof a composition comprising a chemically compatible combination of one or more surfactants and at least one chelating agent, ascorbic acid or a derivative thereof, algae extract, and kelp or sodium sulfite and sodium metabisulfite. | 2013-08-15 |
20130209385 | COSMETIC COMPOSITION WITH WATERTIGHT FRAGRANCE - The present invention refers to a cosmetic composition which, in particular, enables the perfume component resist wash off by water and sweat and to remain fixed on the skin for a long time watertightly. The cosmetic composition comprises fragrance and a fragrance-fixing complex consisting of 0.01-10% by weight of a hydrophobic, alcohol-soluble, carboxylated acrylates/octylacrylamide copolymer and 0.01-10% by weight of a hydrolyzed jojoba ester. Further the complex is able to significantly reduce the total amount of fragrances while giving the same scent feeling to the consumer. | 2013-08-15 |
20130209386 | NEW USES - An antibacterial or anti-acne formulation containing (a) tropone or a substituted tropone and (b) a metal or metal salt selected from copper, copper salts, bismuth, bismuth salts, silver, silver salts, and mixtures thereof, for use in the treatment of either acne or body odour. The substituted tropone may be for example tropolone or hinokitiol. | 2013-08-15 |
20130209387 | Antiperspirant Active Compositions and Manufacture Thereof - An antiperspirant active composition comprising an aluminum salt, the aluminum salt (i) having an aluminum to chloride molar ratio of 0.3:1 to 3:1; and (ii) exhibiting an | 2013-08-15 |
20130209388 | CONDITIONING COMPOSITION ADDITIVE FOR PROVIDING IMMEDIATE AND LONG LASTING BENEFITS TO KERATIN SUBSTRATES - The presently disclosed and claimed inventive concept(s) relates to a conditioning composition additive for use on keratin substrates in order to provide immediate as well as long lasting benefits to the keratin substrate in conditioning systems, such as leave-on and rinse off conditioners, for hair and skin, or for imparting greater water resistance to such personal care compositions as sunscreens or cosmetics. The presently disclosed and claimed inventive concept(s) also relates to a conditioning composition containing the conditioning composition additive and a method of applying the conditioning composition additive. | 2013-08-15 |
20130209389 | LOADED GEL PARTICLES FOR ANTI-FOULING COMPOSITIONS - The present invention provides polishing control components for anti-fouling paints for vessels which comprise rosin or other water-degradable polymers entrapped in gel particles, such as aerogel or aeromosil particles. | 2013-08-15 |
20130209390 | Process For Producing Drug-Block Copolymer Composite And Pharmaceutical Preparation Containing Same - [Problem] There has been a requirement for a process for producing a pharmaceutical preparation that is obtained by encapsulating a uniform poorly water-soluble drug in a block copolymer, and dissolves immediately with an addition of water, and does not contain residues of organic solvents. | 2013-08-15 |
20130209391 | FUNCTIONALIZED POLYMER COMPOSITIONS - The invention relates to functionalized polymers including homopolymers and copolymers and their uses in industrial applications and in agricultural applications. In particular, the homopolymers and copolymers may be, for example, used in polymer blends, used as nutritives and in feed compositions, and used in combination with a pharmaceutical or nutritive. | 2013-08-15 |
20130209392 | HETEROATOM CONTAINING CYCLIC DIMERS - The present invention provides cyclic dimers of alpha acids and polymers derived therefrom. Also provided are processes for preparing and methods of using the cyclic dimers and the polymers derived from the cyclic dimers. | 2013-08-15 |
20130209393 | THERAPEUTIC PEPTIDE COMPOSITIONS AND METHODS - Therapeutic peptide compositions comprise a therapeutic peptide, such as insulin, together with an alkyl N,N-disubstituted amino acetate, such as dodecyl 2-(N,N-dimethylamino) propionate. | 2013-08-15 |
20130209394 | MN/CA IX AND EGFR PATHWAY INHIBITION - The invention is based upon the discovery that the EGFR pathway can stimulate a previously unknown tumorigenic function of CA IX, via phosphorylation of the sole tyrosine residue present in CA IX's intracellular domain. EGFR-phosphorylated CA IX then interacts with the p85 subunit of PI3K to activate Akt, which in turn is associated with anti-apototic function and increased cell survival. The latter finding indicates that there is a positive feedback loop for CA9 expression mediated by the PI3K pathway in preneoplastic/neoplastic diseases. Disclosed herein are novel therapeutic methods for treating preneoplastic/neoplastic diseases associated with abnormal MN/CA IX expression, using EGFR pathway inhibitors. Preferably, the EGFR pathway inhibitors are tyrosine kinase inhibitors or EGFR-specific antibodies. Further disclosed are methods for patient therapy selection for EGFR pathway inhibitors, preferably in combination with other cancer therapies, based on detection of abnormal MN/CA9 gene expression in preneoplastic/neoplastic tissues. | 2013-08-15 |
20130209395 | NUCLEIC ACID MOLECULE ENCODING HEPATITIS B VIRUS CORE PROTEIN AND SURFACE ANTIGEN PROTEIN AND VACCINE COMPRISING THE SAME - Provided herein are nucleic acid sequences encoding hepatitis B virus (HBV) core proteins, surface antigen proteins, fragments and combinations thereof as well as genetic constructs/vectors and vaccines that express said protein sequences. These vaccines are able to induce an immune response peripherally and in the liver by recruiting both cellular and humoral agents. Also provided are methods for prophylactically and/or therapeutically immunizing individuals against HBV. The combination vaccine can also be used for particular design vaccines for particular levels of immune responses to HBV challenge. | 2013-08-15 |
20130209396 | CHIMERIC IL-1 RECEPTOR TYPE I AGONISTS AND ANTAGONISTS - Featured herein are non-naturally occurring cytokine domains that can be used, inter alia, to modulate cellular signalling responsive to interleukin-1 receptor I (IL-1 RI), to treat disorders, and to detect and/or bind to cellular receptors, as well as other agents. Exemplary cytokine domains can contain amino acid residues from at least two parental cytokines domains, for example, receptor binding features, surface features, β strands, and loops from at least two parental cytokines domains. | 2013-08-15 |
20130209397 | HETEROCYCLIC ANTIVIRAL COMPOUNDS - Compounds having the formula (I) wherein R | 2013-08-15 |
20130209398 | CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE - Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium. | 2013-08-15 |
20130209399 | ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASES - The present invention provides the use of IFN-β, an agent that increases the expression of IFN-β, or a polynucleotide which is capable of expressing IFN-β or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. Also provided is IFN-λ for the same purpose. | 2013-08-15 |
20130209400 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS - New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK). | 2013-08-15 |
20130209401 | COMPOSITIONS AND METHODS FOR INHIBITING ENTRY OF A HEPATIC VIRUS - The present invention embraces Niemann-Pick C1-like 1 protein antagonists and agents that inhibit hepatic virus infection for use in the prevention and treatment of a hepatic virus infection. | 2013-08-15 |
20130209402 | HUMAN PAPILLOMAVIRUS E7 ANTIGEN COMPOSITIONS AND USES THEREOF - The present invention relates to human papillomavirus E7 antigen compounds and compositions for treating human papillomavirus infection and associated conditions. The invention provides, in part, polypeptide and nucleic acid molecules including sequences substantially identical to the sequences of two or more human papillomavirus (HPV) E7 antigens, where the E7 antigens are selected from at least two different HPV strains, and methods of using the same. | 2013-08-15 |
20130209403 | USE OF INHIBITORS OF PHOSPHOLIPASE A2 FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTION - The invention relates to Phospholipase A | 2013-08-15 |
20130209404 | Treatment of IBD and IBS Using Both Probiotic Bacteria and Fermented Cereal as Treatment Effectors - The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effector. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease. | 2013-08-15 |
20130209405 | RECOMBINANT BACTERIUM TO DECREASE TUMOR GROWTH - A recombinant bacterium capable of reducing tumor growth is provided, wherein said recombinant bacterium is capable of: a. increased expression of a nucleic acid encoding a chemoreceptor that directs chemotaxis towards tumors, b. accumulation in a quiescent tumor, c. hyper-invasion of a tumor, d. reduced fitness in normal tissue, e. enhanced stimulation of the host innate immune responses, f. delivering a tumor specific DNA vaccine vector to a tumor cell, and g. increased bacterium-induced host programmed cell death. | 2013-08-15 |
20130209406 | RECOMBINANT RNA VIRUSES AND USES THEREOF - Described herein are modified RNA virus gene segments and nucleic acids encoding modified RNA virus gene segments. Also described herein are recombinant RNA viruses comprising modified RNA virus gene segments and the use of such recombinant RNA viruses for the prevention and treatment of disease. | 2013-08-15 |
20130209407 | LIVE MICROBIAL MICROBICIDES - The present invention relates, e.g., to a commensal bacterium which can colonize the genitourinary and/or gastrointestinal mucosa, and which, under suitable conditions, secretes a heterologous antimicrobial polypeptide, wherein the secreted antimicrobial polypeptide is effective to inhibit infectivity by, or a pathogenic activity of, a pathogen. In a most preferred embodiment, the antimicrobial polypeptide inhibits HIV infection (e.g., fusion) and/or pathogenesis. Also described are preventive or therapeutic compositions comprising the commensal bacteria, and methods to inhibit infectivity and/or pathogenesis, using the bacteria. | 2013-08-15 |
20130209408 | BACTERIOPHAGE-CONTAINING THERAPEUTIC AGENTS - The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a bacterial infection characterized by biofilm formation, for example an infection comprising or consisting of | 2013-08-15 |
20130209409 | CHIMERIC ADENOVIRUSES FOR USE IN CANCER TREATMENT - The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index. | 2013-08-15 |
20130209410 | EXPRESSION VECTOR FOR CHOLESTEROL 24 -HYDROLASE IN THERAPY OF HUNTINGTON'S DISEASE - The present invention relates to a vector for use in the treatment of Huntington's disease, which vector comprises a cholesterol 24-hydroxylase encoding nucleic acid. | 2013-08-15 |
20130209411 | Lactocepins For Use in the Treatment of IP-10-Mediated Inflammatory Diseases - The invention relates to lactocepins and/or a functionally active fragment thereof for use in the prophylaxis and/or the treatment of a disease and to one or more lactocepin(s) and/or one or more functionally active fragment(s) thereof for use in the prophylaxis and/or treatment of IP-10-mediated inflammatory diseases. | 2013-08-15 |
20130209412 | FERMENTED FOOD AND METHOD FOR PRODUCING SAME - The purpose of the present invention is to provide a technique whereby the flavor of products such as fermented milk that use the | 2013-08-15 |
20130209413 | USE OF PARVOVIRUS FOR ELIMINATING CANCER STEM CELLS (CSCs) - Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells. | 2013-08-15 |
20130209414 | Expansion Of Stem/Progenitor Cells By Inhibition Of Enzymatic Reactions Catalyzed By The Sir2 Family Of Enzymes - Provided are ex vivo and in vivo methods of expanding renewable stem cells using agents capable of down-regulating Sir2 protein activity and/or expression, expanded populations of renewable stem cells, and uses thereof. | 2013-08-15 |
20130209415 | PURIFIED COMPOSITIONS OF CARDIOVASCULAR PROGENITOR CELLS - Composition and methods are provided for the prospective enrichment of human cardiovascular progenitor cells, which can be differentiated into cardiomyocytes, from in vitro cultures of stem cells. The stem cells are cultured in conditions permissive for differentiation into cardiovascular progenitor cells, and cardiovascular progenitor cells are sorted for expression of one or more of the markers ROR2, CD13, KDR and PDGFαR, where the progenitor cells positively express these markers. Highly enriched populations of cardiomyocyte lineage cells can be obtained. | 2013-08-15 |
20130209416 | METHODS AND COMPOSITIONS FOR PREPARING CARDIOMYOCYTES FROM STEM CELLS AND USES THEREOF - The present invention discloses novel compositions and methods for enhancing cardiac differentiation efficiency of stem cells or promoting ventricular and atrial cardiomyocytes formation from stem cells. The present invention also discloses the atrial and ventricular cardiomyocytes formed from the stem cells, and the uses of the cardiomyocytes for repairing cardiac injuries and screening for new medicaments for treating cardiac injuries. | 2013-08-15 |
20130209417 | ISOLATION OF ADULT MULTIPOTENTIAL CELLS BY TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE - The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells. | 2013-08-15 |
20130209418 | METHODS AND COMPOSITION RELATED TO BROWN ADIPOSE-LIKE CELLS - Methods and therapeutics are provided for treating diseases, including metabolic diseases and other weight-related disorders. Generally, methods for making brown adipose-like including culturing a population of artery-derived cells in adipogenic induction medium for a period of time and under conditions sufficient to increase expression of at least one adipocyte marker at a higher level as compared to untreated artery-derived cells are disclosed. Isolated artery-derived, ex vivo differentiated brown adipose-like cells are also provided, including pharmaceutical compositions and cell delivery systems thereof. In another embodiment, a method of treating a subject is disclosed that includes obtaining a population of artery-derived brown adipose-like cells and administering the brown adipose-like cells into a target region in the subject. | 2013-08-15 |
20130209419 | Methods of Engraftment - Methods and compositions for improving the engraftment of stem cells are described. The method involves administering an effective amount of hemoglobin. The methods and compositions are useful in stimulating hematopoiesis and may be used to boost human hematopoietic re-engraftment for use in transplant recipients or in patients with bone marrow injury. | 2013-08-15 |
20130209420 | Mixed Cell Populations for Tissue Repair and Separation Technique for Cell Processing - The present invention provides a fluid exchange cell culture technique and tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for the production of TRC populations with greater tissue repair and anti-inflammatory capabilities. Embodiments of the present invention include a post-culture process for cultured cells that preferably includes the steps of: a wash process for removing unwanted residual culture components, a volume reduction process, and a harvesting process to remove cultured cells. Preferably, all these steps are performed within a aseptically closed cell culture chamber by implementing a separation method that minimizes mechanical disruption of the cells and is simple to automate. The harvested cells may then be concentrated to a final volume for the intended use. In such embodiments, the final composition is a substantially purified and concentrated cell mixture suspended in a physiologic solution suitable for immediate use in humans without further washing, volume reduction, or processing. Embodiments are also applicable to harvesting (and/or washing) particles within a liquid or solution within a chamber. | 2013-08-15 |
20130209421 | INDUCED PLURIPOTENT STEM CELLS DERIVED FROM HUMAN PANCREATIC BETA CELLS - A method of generating pluripotent stem cells is described. The method comprises:
| 2013-08-15 |
20130209422 | "Pharmaceutical Composition Comprising Stem Cells Treated with NOD2 Agonist or Culture Thereof for Prevention and Treatment of Immune Disorders and Inflammatory Diseases" - The present invention relates to a pharmaceutical composition for the prevention or treatment of immune disorders and inflammatory diseases, comprising stem cells that are generated by culturing stem cells expression Nucleotide-binding Oligomerization Domain protein 2 (NOD2) with a NOD2 agonist or a culture thereof. More particularly, the present invention relates to a method for suppressing immune responses or inflammatory responses of a subject, comprising the step of administering the pharmaceutical composition, the stem cells or culture thereof to the subject, a method for preparing an immunosuppressive drug or an anti-inflammatory drug using the stem cells or culture thereof, a method for preparing PGE | 2013-08-15 |
20130209423 | METHODS FOR PROMOTING HEMATOPOIETIC RECONSTITUTION - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 2013-08-15 |
20130209424 | COMPOSITIONS FOR PROMOTING HEMATOPOIETIC STEM CELL GROWTH - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 2013-08-15 |
20130209425 | ENCAPSULATION OF PANCREATIC CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS - The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation. | 2013-08-15 |
20130209426 | METHOD FOR GENOME MODIFICATION - The present disclosure includes methods for manipulation of the genome, to products obtained or obtainable from such methods, and uses of these products. | 2013-08-15 |
20130209427 | HAIR FOLLICLE NEOGENESIS - This invention provides a skin substitute comprising epithelial cells and modified mesenchymal cells, wherein the modified mesenchymal cells have decreased TSC1/TSC2 function, increased mTORCI function, and/or decreased mTORC2 function compared to wild type mesenchymal cells, and methods for using the same. This invention also provides a method for transplanting cells capable of inducing hair follicles, comprising subdermally or intradermally delivering to a patient modified mesenchymal cells, wherein the modified mesenchymal cells have decreased TSC1/TSC2 function, increased mTORCI function, and/or decreased mTORC2 function compared to wild type mesenchymal cells. | 2013-08-15 |
20130209428 | METHOD OF INDUCING DIFFERENTIATION OF BONE MARROW STROMAL CELLS TO NEURAL PRECURSOR CELLS, NEURAL PRECURSOR CELLS, AND USES THEREOF - There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and/or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and/or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention. | 2013-08-15 |
20130209429 | Modulation of Tissue Fatty Acid Composition of a Host by Human Gut Bacteria - The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria. | 2013-08-15 |
20130209430 | METHODS FOR REGULATION OF STEM CELLS - Methods are provided for increasing stem cells, hematopoietic progenitor/stem cells, mesenchymal progenitor/stem cells, mesodermal progenitor/stem cells, muscle progenitor/stem cells, or neural progenitor/stem cells in vivo in a mammalian subject. Methods are also provided for treating an immune related disease, a mesenchymal/mesoderm degenerative disease, or a neurodegenerative disease in a mammalian subject in need thereof. | 2013-08-15 |
20130209431 | ISOLATION AND CULTURE OF ERYTHROID PROGENITOR CELLS - Disclosed herein are methods of isolating erythroid progenitor cells from a source of human hematopoietic cells and methods of culturing the isolated erythroid progenitor cells in vitro to produce clinically relevant quantities of erythrocytes. | 2013-08-15 |
20130209432 | PRODUCT AND PROCESS FOR LIQUEFACTION OF MUCUS OR SPUTUM - Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system. | 2013-08-15 |
20130209433 | MODULATION OF AMINO ACID METABOLISM IN THE HYPOTHALAMUS - Methods for reducing peripheral blood glucose levels, food intake, glucose production, gluconeogenesis, triglyceride levels, and low density lipoprotein (VLDL) levels in mammals are provided. Also provided are methods of increasing glucose production and food intake in mammals. Further provided are methods of treating a disorder selected from the group consisting of obesity, type 2 diabetes, type 1 diabetes, hyperglycemia, insulin resistance, glucose intolerance, leptin resistance, metabolic syndrome, heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyper-VLDLemia, atherosclerosis, hypercholesterolemia, hypertension, and any combination of the foregoing. The methods involve manipulations of amino acid presence or metabolism in the hypothalamus of the mammal. | 2013-08-15 |
20130209434 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF LEUCYL-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. | 2013-08-15 |
20130209435 | METHODS FOR PREDICTING RISK OF STROKE - The invention provides methods of determining risk for stroke in a patient, as well as methods of determining a subject's need for anti-coagulation therapy. In exemplary embodiments, the method comprises measuring a level of derivatives of reactive oxygen metabolites (DROMs) in a biological sample obtained from the subject, wherein an increased level of DROMs, relative to a control level, is indicative of the subject's need for anticoagulation therapy. Further provided are methods of decreasing risk of stroke in a subject, methods of determining the efficacy of a therapeutic agent, methods of monitoring a subject's risk of stroke, and kits. | 2013-08-15 |
20130209436 | LYSOSOMAL STORAGE DISEASE ENZYMES - The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency. | 2013-08-15 |
20130209437 | I-CREI HOMING ENDONUCLEASE VARIANTS HAVING NOVEL CLEAVAGE SPECIFICITY AND USE THEREOF - A method for engineering I-CreI homing endonuclease variants able to cleave mutant I-CreI sites having variation in positions ±8 to ±10. A I-CreI homing endonuclease variant obtainable by said method, a vector encoding said variant, a cell, an animal or a plant modified by said vector. Use of said I-CreI endonuclease variant and derived products for genetic engineering, genome therapy and antiviral therapy. | 2013-08-15 |
20130209438 | Prostatic Acid Phosphatase for the Treatment of Pain - Methods and compositions are provided for the treatment of pain and cystic fibrosis. The methods include administering to an animal a composition or a pharmaceutical formulation comprising a therapeutically effective amount of a Prostatic Acid Phosphatase (“PAP”) polypeptide, or an active variant, fragment or derivative thereof, or a therapeutically effective amount of an activity enhancing PAP modulator. PAP is provided as a treatment for chronic pain including neuropathic and inflammatory pain in animals and humans. The PAP, or the active variant, fragment or derivative thereof, or the activity enhancing modulator of the PAP is administered via one or more of injection, intrathecal injection, oral administration, a surgically implanted pump, stem cells, viral gene therapy, or naked DNA gene therapy. Intrathecal injection of PAP functions as an analgesic and reduces thermal sensitivity in mice. PAP can reduce chronic mechanical and thermal inflammatory pain in mice. Allodynia and hyperalgesia due to nerve injury can be prevented by increasing PAP activity in spinal cord. | 2013-08-15 |
20130209439 | INHIBITORS OF PDE4 BINDING TO HSP20 - The present invention provides methods and materials for use in increasing HSP20 activation in a biological system, for example by increasing phosphorylation of Ser16 of HSP20. In one aspect, the invention provides a method for increasing HSP20 activation in a biological system, comprising contacting the system with an antagonist capable of inhibiting PDE4 binding to HSP20, the antagonist comprising or consisting essentially of a fragment of PDE4 or an analogue thereof. In a further aspect the invention provides a method of screening for an agent able to increase activation of HSP20. A preferred antagonist has a C-terminal lysine residue. | 2013-08-15 |
20130209440 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INSULIN-ASSOCIATED MEDICAL CONDITIONS - A method of increasing insulin content in a pancreatic beta cell is disclosed. The method comprising expressing in the pancreatic beta cell an exogenous polynucleotide encoding at least one microRNA or a precursor thereof, wherein the microRNA is selected from the group consisting of miR-15, miR-16, miR-24, miR-26, miR-27, miR-29, miR-30, miR-129, miR-141, miR-148, miR-182, miR-200, miR-376 and Let-7, thereby increasing the insulin content in the pancreatic beta cell. | 2013-08-15 |
20130209441 | PROCESS FOR INHIBITION OF CEREBRAL DAMAGE ASSOCIATED WITH ISCHEMIA BY ANTHOCYANINS AND ANTHOCYANIDINS - A process is provided for inhibition of neural damage associated with an ischemic event that includes the administration of anthocyanin compound to a subject. After allowing sufficient time for the anthocyanin compound to reach the situs of the ischemic event, inhibition of neural damage associated with the ischemic event occurs. Neural damage is further inhibited by administration of the anthocyanin compound in conjunction with an agent effective in and specifically including tissue plasminogen activator. The anthocyanin compound in specific embodiments is in pure form or a mixture of two or more anthocyanins, or anthocyanidins or aglycones thereof, with the mixture being a natural product extract. | 2013-08-15 |
20130209442 | WOUND CLEANING CHEMICAL COMPOSITION AND METHOD FOR MANUFACTURING - A wound cleaning chemical composition that includes an unpurified saline solution in the range of 1.5 to 3 grams per cc, a lactoferrin solution in the range of 0.001% to 1.5% by volume, an ethanol solution in the range of 0.05% to 1.5% by volume, a sodium bicarbonate solution in the range of 1.2% to 5.1% by volume and a hypochlorite solution in the range of 0.06% to 4.7% by volume. The wound cleaning chemical composition also includes a method for manufacturing a wound cleaning chemical composition that includes the steps of preparing an unpurified saline solution, adding a hypochlorite solution, an ethanol solution and a sodium bicarbonate solution to the unpurified saline solution and adding a lactoferrin solution. | 2013-08-15 |
20130209443 | Method for Treating Oncological Diseases - A method to treat solid tumors and other oncological diseases consists of parenterally injecting an agent which destroy's blood's extracellular DNA into the systemic blood circulation of a cancer patient to slow down malignant. The agent is embodied in the form of a DNAse enzyme and, more particularly, as a bovine pancreatic DNAse. Doses from 50,000-250,000,000 Kunz units/day are injected for 5-360 days. A binding agent or an agent that modifies the chemical composition of the blood extracellular DNA is additionally injected into the blood. This modifying agent is preferably an enzyme-ribonuclease. | 2013-08-15 |
20130209444 | NON-ANTICOAGULANT SULFATED OR SULFONATED POLYSACCHARIDES - The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process. | 2013-08-15 |
20130209445 | Optimized Fc Variants - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 2013-08-15 |
20130209446 | Copy Number Variant-Dependent Genes As Diagnostic Tools, Predictive Biomarkers And Therapeutic Targets - Provided herein are methods of diagnosing and/or treating malignant or pre-malignant conditions in a subject. Overexpression of copy number variant-dependent genes, e.g., genes encoding a cell surface receptor, resulting from copy number changes compared to control is diagnostic of the condition, such as multiple myeloma or monoclonal gammopathy of undetermined significance. Also provided are methods for treating malignant conditions, such as multiple myeloma or a hyperdiploid subtype, with therapeutic agents, with or without other anti-cancer drugs, to downrregulate the overexpressed CNV genes and/or up-regulate the underexpressed genes. Furthermore, methods for lowering drug resistance in multiple myeloma cells via inhibition of platelet activation or thrombin release and for increasing survivability of a multiple myeloma subject via lithibition of PSMD4 gene to increase b-catenin protein expression are provided. | 2013-08-15 |
20130209447 | METHODS AND KITS FOR PREDICTING THE RISK OF DIABETES ASSOCIATED COMPLICATIONS USING GENETIC MARKERS AND ARRAYS - A method for diagnosing a genetic predisposition in a subject for diseases, disorders or conditions including a diabetic kidney complication such as kidney disease of type 2 diabetes or type 1 diabetes, end stage renal disease (ESRD) due to type 2 diabetes, ESRD due to hypertension in type 2 diabetes, ESRD due to type 1 diabetes; cardiovascular diseases due to type 2 diabetes or type 1 diabetes such as atherosclerotic peripheral vascular disease, hypertension, ischemic cardiomyopathy, and myocardial infarction due to type 2 diabetes or type 1 diabetes; and cerebrovascular accident due to type 2 diabetes. At least one polynucleotide is analyzed to detect a single nucleotide polymorphism (SNP), in which the presence of the single nucleotide polymorphism indicates that the subject is suffering from, at risk for, or suspected of suffering from the diseases, disorders or conditions. Also provided is an array or kit for diagnosing the genetic predisposition. | 2013-08-15 |
20130209448 | Carrier Nanoparticles and Related Compositions, Methods and Systems - Carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a boronic acid, configured to present the polymer containing a boronic acid to an environment external to the nanoparticle and related compositions, methods and systems. | 2013-08-15 |
20130209449 | ANTI-PSGL-1 ANTIBODIES AND USES THEREOF - Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein. | 2013-08-15 |
20130209450 | Compositions and Methods for Treating Glioblastoma GBM - Methods of treating a malignant glioma in a subject are disclosed. The methods comprise administering to the subject a therapeutically effective amount of a viral vector comprising: (i) a first polynucleotide sequence encoding a Fas-chimera (Fas-c), said first polynucleotide sequence comprising SEQ ID NOs: 2 and 3; and (ii) a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter. | 2013-08-15 |
20130209451 | Treatments for Cancer - The present invention provides methods for reducing tumor survival, expansion, and metastasis. In particular, the invention provides methods for reducing pancreatic tumor survival, expansion, and metastasis. The invention also provides agents for use in the methods, particularly agents that reduce the level or activity of connective tissue growth factor (CTGF), and methods for identifying such agents. | 2013-08-15 |
20130209452 | GENE DEFECTS AND MUTANT ALK KINASE IN HUMAN SOLID TUMORS - Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have been identified herein in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides. | 2013-08-15 |
20130209453 | USE OF TAU TO MONITOR IMMUNOTHERAPY - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau. | 2013-08-15 |
20130209454 | ANTI-HIV ANTIBODIES HAVING INCREASED POTENCY AND BREADTH - Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) antibodies having improved potency and breadth. | 2013-08-15 |
20130209455 | Humanized Anti-CDCP1 Antibodies - The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2013-08-15 |
20130209456 | SUBTYPES OF HUMANIZED ANTIBODY AGAINST INTERLEUKIN-6 RECEPTOR - An antibody subtype (1) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which one C-terminal of the heavy chain is Pro-NH | 2013-08-15 |
20130209457 | Optimized Fc Variants - The present invention relates to a variant Fc region comprising an amino acid substitution at position 238 of the Fc region as compared to a human parent Fc region, wherein the variant Fc region comprises a 238D substitution, wherein the variant Fc region binds FcγRIIb with increased binding affinity compared to a human parent Fc region. | 2013-08-15 |
20130209458 | FAB-GLYCOSYLATED ANTIBODIES - The present invention pertains to a method for controlling the circulation half-life of antibodies by adjusting the amount of sialic acid in the carbohydrates attached to the Fab part of the antibodies. Furthermore, the present invention provides antibodies having an increased circulation half-life. | 2013-08-15 |
20130209459 | TREATMENT WITH ANTI-ErbB2 ANTIBODIES - The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient. | 2013-08-15 |
20130209460 | METHODS AND KITS USED IN IDENTIFYING GLIOBLASTOMA - The invention encompasses methods and kits used in the identification of invasive glioblastoma based upon the expression of TROY. The methods and kits also allow prediction of disease outcome as well as therapeutic outcome. | 2013-08-15 |
20130209461 | Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members - A method for treating an Epidermal Growth Factor Receptor (EGFR) dependent diseases or diseases that have acquired resistance to agents that target EGFR family members comprising administering a therapeutically effective amount of a compound of formula (I) | 2013-08-15 |
20130209462 | CERBERUS/COCO DERIVATIVES AND USES THEREOF - The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives. | 2013-08-15 |
20130209463 | POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS AND OTHER AUTOIMMUNE DISORDERS - This invention relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders. | 2013-08-15 |
20130209464 | POLYPEPTIDES HAVING ANTIVIRAL ACTIVITY AND METHODS FOR USE THEREOF - A polypeptide is provided that comprises an actinohivin variant polypeptide having an amino acid sequence selected from SEQ ID NOS: 4-12. The polypeptide can be provided as part of a fusion protein that includes the actinohivin variant polypeptide and either a fragment crystallizable domain of an antibody (Fc), a fragment antigen-binding domain of an antibody (Fab), or a single chain variable fragment of an antibody (scFv). Isolated nucleic acid molecules encoding the polypeptides are also provided along with vectors and plant cells capable of expressing the polypeptides. Methods of treating an infection of a subject by an enveloped virus are further provided and include administering an effective amount of the polypeptides to a subject. | 2013-08-15 |